CN107645954A - 多发性骨髓瘤的罗尼哌他组合治疗 - Google Patents

多发性骨髓瘤的罗尼哌他组合治疗 Download PDF

Info

Publication number
CN107645954A
CN107645954A CN201680012508.0A CN201680012508A CN107645954A CN 107645954 A CN107645954 A CN 107645954A CN 201680012508 A CN201680012508 A CN 201680012508A CN 107645954 A CN107645954 A CN 107645954A
Authority
CN
China
Prior art keywords
use according
melphalan
roniperstat
kit
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680012508.0A
Other languages
English (en)
Chinese (zh)
Inventor
拉尔夫·D·桑德森
维士努·普拉卡什·C·拉马尼
亚历山大·诺塞达
保拉·巴尔维里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Of Lidice Ante Biological Science Ltd By Share Ltd i L
UAB Research Foundation
Original Assignee
Of Lidice Ante Biological Science Ltd By Share Ltd i L
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Of Lidice Ante Biological Science Ltd By Share Ltd i L, UAB Research Foundation filed Critical Of Lidice Ante Biological Science Ltd By Share Ltd i L
Publication of CN107645954A publication Critical patent/CN107645954A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201680012508.0A 2015-03-06 2016-03-03 多发性骨髓瘤的罗尼哌他组合治疗 Pending CN107645954A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562129221P 2015-03-06 2015-03-06
US62/129,221 2015-03-06
US201562153899P 2015-04-28 2015-04-28
US62/153,899 2015-04-28
PCT/IB2016/051196 WO2016142814A1 (en) 2015-03-06 2016-03-03 Roneparstat combined therapy of multiple myeloma

Publications (1)

Publication Number Publication Date
CN107645954A true CN107645954A (zh) 2018-01-30

Family

ID=55521766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680012508.0A Pending CN107645954A (zh) 2015-03-06 2016-03-03 多发性骨髓瘤的罗尼哌他组合治疗

Country Status (16)

Country Link
US (1) US10576101B2 (enExample)
EP (2) EP3265075B1 (enExample)
JP (1) JP2018512394A (enExample)
KR (1) KR20170138405A (enExample)
CN (1) CN107645954A (enExample)
AU (1) AU2016230859A1 (enExample)
BR (1) BR112017018869A2 (enExample)
CA (1) CA2978040A1 (enExample)
DK (1) DK3265075T3 (enExample)
ES (1) ES2715556T3 (enExample)
HK (1) HK1245107A1 (enExample)
HU (1) HUE042681T2 (enExample)
MX (1) MX2017011093A (enExample)
PL (1) PL3265075T3 (enExample)
PT (1) PT3265075T (enExample)
WO (1) WO2016142814A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317281A2 (en) * 1987-11-19 1989-05-24 The Wellcome Foundation Limited Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
SK288335B6 (sk) 2001-09-12 2016-02-02 Sigma-Tau Research Switzerland S.A. Čiastočne alebo úplne N-desulfatovaný, N-reacetylovaný heparín, spôsob jeho prípravy, jeho použitie na prípravu liečiva s inhibičným účinkom na heparanázu, s antiangiogénnym a protizápalovým účinkom a farmaceutický prostriedok s jeho obsahom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317281A2 (en) * 1987-11-19 1989-05-24 The Wellcome Foundation Limited Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.P.RITCHIE等: "SST0001，a chemically modified heparin,inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis", 《CLINICAL CANCER RESEARCH》 *

Also Published As

Publication number Publication date
AU2016230859A1 (en) 2017-08-17
EP3265075A1 (en) 2018-01-10
HK1245107A1 (zh) 2018-08-24
US20180050061A1 (en) 2018-02-22
HUE042681T2 (hu) 2019-07-29
PL3265075T3 (pl) 2020-10-05
PT3265075T (pt) 2019-03-25
WO2016142814A1 (en) 2016-09-15
DK3265075T3 (en) 2019-04-08
BR112017018869A2 (pt) 2018-04-17
JP2018512394A (ja) 2018-05-17
MX2017011093A (es) 2018-02-19
KR20170138405A (ko) 2017-12-15
CA2978040A1 (en) 2016-09-15
EP3453389A1 (en) 2019-03-13
EP3265075B1 (en) 2018-12-12
ES2715556T3 (es) 2019-06-04
US10576101B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
DK2582683T3 (en) TREATMENT OF Gout and Hyperuricemia
AU2021297716A1 (en) Combination therapy for treatment of cancer
KR20160072261A (ko) 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
JP2024028865A (ja) 抗ｃｄ１９抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム
CN118946371A (zh) 靶向psma的放射性药物和检查点抑制剂的组合疗法
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
CN107645954A (zh) 多发性骨髓瘤的罗尼哌他组合治疗
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
CA2829130A1 (en) Ezatiostat for treating multiple myeloma
WO2024175106A1 (zh) Pd-l1小分子抑制剂与抗体的药物组合及其应用
JP2023509158A (ja) 腫瘍治療の医薬組み合わせとその使用
MX2011009301A (es) Composiciones y metodos para tratar sindrome mielodisplasico.
HK1189515B (en) Methods of treating multiple myeloma using combination therapies based on huluc63 with bortezomib
HK1233169A (en) Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
HK1233169A1 (en) Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
KR20130020944A (ko) 골수이형성 증후군을 치료하기 위한 조성물 및 방법
HK1129853B (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
WO2013019222A1 (en) Compositions and methods for treating myelodysplastic syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1245107

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180130

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1245107

Country of ref document: HK